NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

移植物抗宿主病 (GVHD) :流行病學預測

Graft versus host disease (GVHD)- Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 601915
出版日期 按訂單生產 內容資訊 英文 50 Pages
商品交期: 2-10個工作天內
價格
移植物抗宿主病 (GVHD) :流行病學預測 Graft versus host disease (GVHD)- Epidemiology Forecast to 2028
出版日期: 按訂單生產內容資訊: 英文 50 Pages
簡介

本報告提供美國,EU5個國家 (德國,西班牙,義大利,法國,英國) 、日本的移植物抗宿主病 (GVHD) 治療藥市場相關調查分析,提供疾病概要,流行病學 (實際成果·預測) 相關的系統性資訊。

第1章 報告概要

第2章 移植物抗宿主病 (GVHD) 流行病學概要

第3章 移植物抗宿主病 (GVHD) 市場佔有率分佈

第4章 疾病的背景和概要:移植物抗宿主病 (GVHD)

  • 簡介
  • 疾病的種類
  • 急性GVHD
  • 慢性GVHD
  • GVHD的等級
  • 病理生理學
  • GVHD的危險因素
  • 診斷

第5章 流行病學和患者人口

  • 主要調查結果
  • 美國
  • EU5個國家
  • 前提條件與根據
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第6章 未滿足需求

第7章 附錄

第8章 調查手法

第9章 資訊來源

第10章 諮詢服務

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI0006

DelveInsight's "Graft versus host disease (GVHD) - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Graft versus host disease (GVHD) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Graft versus host disease (GVHD) Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Graft versus host disease (GVHD) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Graft versus host disease (GVHD) outlook. It also includes the explanation of changing trends of epidemiology outlining the Graft versus host disease (GVHD) scenario.

Graft versus host disease (GVHD) Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Graft versus host disease (GVHD) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

  • The report covers detailed overview of Graft versus host disease (GVHD) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Graft versus host disease (GVHD) Report assesses the disease risk and burden and highlights the unmet needs
  • It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Total Cases in Graft versus host disease (GVHD)

Key assessments

  • Patient Segmentation in Graft versus host disease (GVHD)
  • Graft versus host disease (GVHD) Risk & Burden
  • Factors driving growth in a specific Graft versus host disease (GVHD) patient population

Table of Contents

1. Report Introduction

2. Graft versus host disease (GVHD) Epidemiology Overview at a Glance

  • 2.1. Patient Share Distribution of Graft versus host disease (GVHD) in 2016
  • 2.2. Patient Share Distribution of Graft versus host disease (GVHD) in 2028

3. Disease Background and Overview: Graft versus host disease (GVHD)

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Graft versus host disease (GVHD) in 7MM
  • 4.3. Total Prevalent/ Incident Patient Population of Graft versus host disease (GVHD) in 7MM - By Countries

5. Epidemiology of Graft versus host disease (GVHD) by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Graft versus host disease (GVHD)
    • 5.1.3. Sub-Type Specific cases of the Graft versus host disease (GVHD) *
    • 5.1.4. Sex- Specific Cases of the Graft versus host disease (GVHD)*
    • 5.1.5. Diagnosed Cases of the Graft versus host disease (GVHD)
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Graft versus host disease (GVHD)
    • 5.4.3. Sub-Type Specific cases of the Graft versus host disease (GVHD)*
    • 5.4.4. Sex- Specific Cases of the Graft versus host disease (GVHD)*
    • 5.4.5. Diagnosed Cases of the Graft versus host disease (GVHD)
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Graft versus host disease (GVHD)
    • 5.5.3. Sub-Type Specific cases of the Graft versus host disease (GVHD)*
    • 5.5.4. Sex- Specific Cases of the Graft versus host disease (GVHD)*
    • 5.5.5. Diagnosed Cases of the Graft versus host disease (GVHD)
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Graft versus host disease (GVHD)
    • 5.6.3. Sub-Type Specific cases of the Graft versus host disease (GVHD)*
    • 5.6.4. Sex- Specific Cases of the Graft versus host disease (GVHD)*
    • 5.6.5. Diagnosed Cases of the Graft versus host disease (GVHD)
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Graft versus host disease (GVHD)
    • 5.7.3. Sub-Type Specific cases of the Graft versus host disease (GVHD)*
    • 5.7.4. Sex- Specific Cases of the Graft versus host disease (GVHD)*
    • 5.7.5. Diagnosed Cases of the Graft versus host disease (GVHD)
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Graft versus host disease (GVHD)
    • 5.8.3. Sub-Type Specific cases of the Graft versus host disease (GVHD)*
    • 5.8.4. Sex- Specific Cases of the Graft versus host disease (GVHD)*
    • 5.8.5. Diagnosed Cases of the Graft versus host disease (GVHD)
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Graft versus host disease (GVHD)
    • 5.9.3. Sub-Type Specific cases of the Graft versus host disease (GVHD)*
    • 5.9.4. Sex- Specific Cases of the Graft versus host disease (GVHD)*
    • 5.9.5. Diagnosed Cases of the Graft versus host disease (GVHD)

6. Unmet Needs of the Graft versus host disease (GVHD)

7. Appendix

8. Report Methodology

  • 8.1. Sources

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Graft versus host disease (GVHD) in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Graft versus host disease (GVHD) in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Graft versus host disease (GVHD) in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Graft versus host disease (GVHD) in United States (2016-2028)*
  • Table 5: Sex- Specific Cases of the Graft versus host disease (GVHD) in United States (2016-2028)*
  • Table 6: Diagnosed Cases of the Graft versus host disease (GVHD) in United States (2016-2028)
  • Table 7: Prevalent/Incident Cases of the Graft versus host disease (GVHD) in Germany (2016-2028)
  • Table 8: Sub-Type Specific cases of the Graft versus host disease (GVHD) in Germany (2016-2028) *
  • Table 9: Sex- Specific Cases of the Graft versus host disease (GVHD) in Germany (2016-2028) *
  • Table 10: Diagnosed Cases of the Graft versus host disease (GVHD) in Germany (2016-2028)
  • Table 11: Prevalent/Incident Cases of the Graft versus host disease (GVHD) in France (2016-2028)
  • Table 12: Sub-Type Specific cases of the Graft versus host disease (GVHD) in France (2016-2028) *
  • Table 13: Sex- Specific Cases of the Graft versus host disease (GVHD) in France (2016-2028) *
  • Table 14: Diagnosed Cases of the Graft versus host disease (GVHD) in France (2016-2028)
  • Table 15: Prevalent/Incident Cases of the Graft versus host disease (GVHD) in Italy (2016-2028)
  • Table 16: Sub-Type Specific cases of the Graft versus host disease (GVHD) in Italy (2016-2028) *
  • Table 17: Sex- Specific Cases of the Graft versus host disease (GVHD) in Italy (2016-2028) *
  • Table 18: Diagnosed Cases of the Graft versus host disease (GVHD) in Italy (2016-2028)
  • Table 19: Prevalent/Incident Cases of the Graft versus host disease (GVHD) in Spain (2016-2028)
  • Table 20: Sub-Type Specific cases of the Graft versus host disease (GVHD) in Spain (2016-2028) *
  • Table 21: Sex- Specific Cases of the Graft versus host disease (GVHD) in Spain (2016-2028) *
  • Table 22: Diagnosed Cases of the Graft versus host disease (GVHD) in Spain (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Graft versus host disease (GVHD) in UK (2016-2028)
  • Table 24: Sub-Type Specific cases of the Graft versus host disease (GVHD) in UK (2016-2028) *
  • Table 25: Sex- Specific Cases of the Graft versus host disease (GVHD) in UK (2016-2028) *
  • Table 26: Diagnosed Cases of the Graft versus host disease (GVHD) in UK (2016-2028)
  • Table 27: Prevalent/Incident Cases of the Graft versus host disease (GVHD) in Japan (2016-2028)
  • Table 28: Sub-Type Specific cases of the Graft versus host disease (GVHD) in Japan (2016-2028) *
  • Table 29: Sex- Specific Cases of the Graft versus host disease (GVHD) in Japan (2016-2028) *
  • Table 30: Diagnosed Cases of the Graft versus host disease (GVHD) in Japan (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Graft versus host disease (GVHD) in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Graft versus host disease (GVHD) in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Graft versus host disease (GVHD) in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Graft versus host disease (GVHD) in United States (2016-2028)*
  • Figure 5: Sex- Specific Cases of the Graft versus host disease (GVHD) in United States (2016-2028)*
  • Figure 6: Diagnosed Cases of the Graft versus host disease (GVHD) in United States (2016-2028)
  • Figure 7: Prevalent/Incident Cases of the Graft versus host disease (GVHD) in Germany (2016-2028)
  • Figure 8: Sub-Type Specific cases of the Graft versus host disease (GVHD) in Germany (2016-2028) *
  • Figure 9: Sex- Specific Cases of the Graft versus host disease (GVHD) in Germany (2016-2028) *
  • Figure 10: Diagnosed Cases of the Graft versus host disease (GVHD) in Germany (2016-2028)
  • Figure 11: Prevalent/Incident Cases of the Graft versus host disease (GVHD) in France (2016-2028)
  • Figure 12: Sub-Type Specific cases of the Graft versus host disease (GVHD) in France (2016-2028) *
  • Figure 13: Sex- Specific Cases of the Graft versus host disease (GVHD) in France (2016-2028) *
  • Figure 14: Diagnosed Cases of the Graft versus host disease (GVHD) in France (2016-2028)
  • Figure 15: Prevalent/Incident Cases of the Graft versus host disease (GVHD) in Italy (2016-2028)
  • Figure 16: Sub-Type Specific cases of the Graft versus host disease (GVHD) in Italy (2016-2028) *
  • Figure 17: Sex- Specific Cases of the Graft versus host disease (GVHD) in Italy (2016-2028) *
  • Figure 18: Diagnosed Cases of the Graft versus host disease (GVHD) in Italy (2016-2028)
  • Figure 19: Prevalent/Incident Cases of the Graft versus host disease (GVHD) in Spain (2016-2028)
  • Figure 20: Sub-Type Specific cases of the Graft versus host disease (GVHD) in Spain (2016-2028) *
  • Figure 21: Sex- Specific Cases of the Graft versus host disease (GVHD) in Spain (2016-2028) *
  • Figure 22: Diagnosed Cases of the Graft versus host disease (GVHD) in Spain (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Graft versus host disease (GVHD) in UK (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Graft versus host disease (GVHD) in UK (2016-2028) *
  • Figure 25: Sex- Specific Cases of the Graft versus host disease (GVHD) in UK (2016-2028) *
  • Figure 26: Diagnosed Cases of the Graft versus host disease (GVHD) in UK (2016-2028)
  • Figure 27: Prevalent/Incident Cases of the Graft versus host disease (GVHD) in Japan (2016-2028)
  • Figure 28: Sub-Type Specific cases of the Graft versus host disease (GVHD) in Japan (2016-2028) *
  • Figure 29: Sex- Specific Cases of the Graft versus host disease (GVHD) in Japan (2016-2028) *
  • Figure 30: Diagnosed Cases of the Graft versus host disease (GVHD) in Japan (2016-2028)